<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3112246510
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GLERAN 30MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PIOGLITAZONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Jar
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        45.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UNITED PHARMACEUTICAL COMPANY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL CO.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BG03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group:<br />Anti-diabetic.<br />Therapeutic indications:<br />Gleran&reg; contains pioglitazone. It is an anti-diabetic medicine used to treat type 2 (non-insulin dependent) diabetes mellitus, when metformin is not suitable or has failed to work adequately. This is the diabetes that usually develops in adulthood.<br />Gleran&reg; helps control the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces. Your doctor will check whether Gleran&reg; is working 3 to 6 months after you start taking it.<br />Gleran&reg; may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as metformin, sulphonylurea or insulin) which have failed to provide sufficient control of blood sugar.<br />This medicine is for diagnostic use only.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take Gleran&reg;</strong><br />- If you are hypersensitive (allergic) to pioglitazone or any of the other ingredients of Gleran&reg;.<br />- If you have heart failure or have had heart failure in the past.<br />- If you have liver disease.<br />- If you have had diabetic ketoacidosis (a complication of diabetes causing rapid weight loss, nausea or vomiting).<br />- If you have or have ever had bladder cancer.</p><p>- If you have blood in your urine that your doctor has not checked.<br /><strong>b. Take special care with Gleran&reg; tablets</strong><br />Tell your doctor before you start to take this medicine<br />Cardiac Failure and Other Cardiac Effects: Pioglitozone, like other thiazolidinediones, can cause fluid retention when used alone or in combination with other antidiabetic agents, including insulin. Fluid retention may lead to or exacerbate heart failure. Patients should be observed for signs and symptoms of heart failure. If these signs and symptoms develop, the heart failure should be managed according to current standards of core.<br />Furthermore, discontinuation or dose reduction of Pioglitozone must be considered<br />There may be an increased chance of having bladder cancer when you take Pioglitazone.<br />- If you retain water (fluid retention) or have heart failure problems in particular if you are over 75 years old. If you take anti-inflammatory medicines which can also cause fluid retention and swelling, you must also tell your doctor.<br />- If you have a special type of diabetic eye disease called macular oedema (swelling of the back of the eye).<br />- If you have cysts on your ovaries (polycystic ovary syndrome). There may be an increased possibility of becoming pregnant because you may ovulate again when you take Gleran&reg;. If this applies to you, use appropriate contraception to avoid the possibility of an unplanned pregnancy.<br />- If you have a problem with your liver or heart. Before you start taking<br />Gleran&reg; you will have a blood sample taken to check your liver function. This check may be repeated at intervals. Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with Gleran&reg; and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).<br />- If you take Gleran&reg; with other medicines for diabetes, it is more likely that your blood sugar could fall below the normal level (hypoglycaemia).<br />You may also experience a reduction in blood count (anaemia).<br />Broken bones<br />A higher number of bone fractures was seen in patients, particularly women taking pioglitazone. Your doctor will take this into account when treating your diabetes.<br />Children<br />Use in children under 18 years is not recommended.<br /><strong>c. Taking other medicines, herbal or dietary supplements</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.<br />You can usually continue to take other medicines whilst you are being treated with Gleran&reg;. However, certain medicines are especially likely to affect the amount of sugar in your blood:<br />- Gemfibrozil (used to lower cholesterol).<br />- Rifampicin (used to treat tuberculosis and other infections).<br />Tell your doctor or pharmacist if you are taking any of these. Your blood sugar will be checked, and your dose of Gleran&reg; may need to be changed.<br /><strong>d. Taking Gleran&reg; with food and drink</strong><br />You may take your tablets with or without food. You should swallow the tablets with a glass of water.<br /><strong>e. Pregnancy and breast-feeding</strong><br />Tell your doctor if<br />- You are, you think you might be or are planning to become pregnant.<br />- You are breast-feeding or if you are planning to breast-feed your baby.<br />Your doctor will advise you to discontinue this medicine.<br /><strong>f. Driving and using machines</strong><br />Pioglitazone will not affect your ability to drive or use machines but take care if you experience abnormal vision.<br /><strong>g. Important information about some of the ingredients of Gleran&reg;</strong><br />Gleran&reg; tablets contain lactose. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>One tablet of 15 mg, 30 mg or 45 mg of pioglitazone should be taken once daily. If necessary your doctor may tell you to take a different dose.<br />If you have the impression that the effect of Gleran&reg; is too weak, talk to your doctor.<br />When Gleran&reg; is taken in combination with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether you need to take a smaller dose of your medicines.<br />Your doctor will ask you to have blood tests periodically during treatment with Gleran&reg;. This is to check that your liver is working normally.<br />If you are following a diabetic diet, you should continue with this while you are taking Gleran&reg;.<br />Your weight should be checked at regular intervals; if your weight increases, inform your doctor.<br /><strong>a. If you take more Gleran&reg; than you should</strong><br />If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately. Your blood sugar could fall below the normal level and can be increased by taking sugar. It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice.<br /><strong>b. If you forget to take Gleran&reg;</strong><br />Take Gleran&reg; daily as prescribed. However if you miss a dose, just carry on with the next dose as normal. Do not take a double dose to make up for a forgotten tablet.<br /><strong>c. If you stop taking Gleran&reg;</strong><br />Gleran&reg; should be used every day to work properly. If you stop using<br />Gleran&reg;, your blood sugar may go up. Talk to your doctor before stopping this treatment.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Gleran&reg; can cause side effects, although not everbody gets them.<br />In particular, patients have experienced the following serious side effects:<br />Heart failure has been experienced commonly (1 to 10 users in 100) in patients taking Gleran&reg; in combination with insulin. Symptoms are unusual shortness of breath or rapid increase in weight or localised swelling (oedema). If you experience any of these, especially if you are over the age of 65, seek medical advice straight away.<br />Bladder cancer has been experienced uncommonly (1 to 10 users in 1000) in patients taking Gleran&reg;.<br />Signs and symptoms include blood in your urine, pain when urinating or a sudden need to urinate. If you experience any of these, talk to your doctor as soon as possible.<br />Localised swelling (oedema) has also been experienced very commonly in patients taking Gleran&reg;in combination with insulin. If you experience this side effect, talk to your doctor as soon as possible.<br />Broken bones have been reported commonly (1 to 10 users in 100) in women patients taking Gleran&reg;. If you experience this side effect, talk to your doctor as soon as possible.<br />Blurred vision due to swelling (or fluid) at the back of the eye (frequency not known) has also been reported in patients taking Gleran&reg;. If you experience this symptom for the first time, talk to your doctor as soon as possible. Also, if you already have blurred vision and the symptom gets worse, talk to your doctor as soon as possible.<br />Allergic reactions have been reported (frequency not known) in patients taking Gleran&reg;. If you have a serious allergic reaction, including hives and swelling of the face, lips, tongue, or throat that may cause difficulty in breathing or swallowing stop taking this medicine and talk to your doctor as soon as possible.<br />The other side effects that have been experienced by some patients taking Gleran&reg; are:<br />Common (affects 1 to 10 users in 100)<br />- Respiratory infection</p><p>- Abnormal vision<br />- Weight gain<br />- Numbness<br />Uncommon (affects 1 to 10 users in 1,000)<br />- Inflammation of the sinuses (sinusitis)<br />- Difficulty sleeping (insomnia)<br />Not known (frequency cannot be estimated from the available data)<br />- Increase in liver enzymes<br />- Allergic reactions<br />The other side effects that have been experienced by some patients when Gleran&reg; is taken with other antidiabetic medicines are:<br />Very common (affects more than 1 user in 10)<br />- Decreased blood sugar (hypoglycaemia)<br />Common (affects 1 to 10 users in 100)<br />- Headache<br />- Dizziness<br />- Joint pain<br />- Impotence<br />- Back pain<br />- Shortness of breath<br />- Small reduction in red blood cell count<br />- Flatulence<br />Uncommon (affects 1 to 10 users in 1,000)<br />- Sugar in urine, proteins in urine<br />- Increase in enzymes<br />- Spinning sensation (vertigo)<br />- Sweating<br />- Tiredness<br />- Increased appetite<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach and sight of children.<br />- Store below 30&ordm;C, protected from moisture.<br />- Do not use Gleran&reg; after the expiry date (Exp. Date) which is stated on the outer pack. The expiry date refers to the last day of that month.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is Pioglitazone.<br />Gleran&reg; 15: Each tablet contains Pioglitazone Hydrochloride equivalent to 15 mg<br />Pioglitazone.<br />Gleran&reg; 30: Each tablet contains Pioglitazone Hydrochloride equivalent to 30 mg Pioglitazone.<br />&bull; The other ingredients are: Lactose, Hydrxypropyl cellulose, Calcium carboxymethyl cellulose, Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                • Tablets
• Physical Description:
Gleran® 15mg Tablets: White rounded square tablets, flat embossed with E44 on one side & multifaceted plain on the other.
Gleran® 30mg Tablets: White 7mm round flat tablets embossed with T54.
• Gleran® is available in the pack size of 30 tablets/jar/pack.
Hospital packs are also available.
Gleran® Tablets are packed in white polyethylene jar enclosed with white polyethylene child resistance cap containing silica gel bags, then labeled with colored adhesive label in colored carton box with a multi folded leaflet.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,<br />Riyadh, Kingdome Saudi Arabia.<br />info-ksa@mspharma.com<br /><strong>Manufacturer by:</strong><br />United Pharmaceutical Mfg. Co. Ltd. for MS Pharma-Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Jan /2020
SPM190581
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المجموعة </strong><strong>الدوائية</strong><strong>:</strong><strong> </strong>لعلاج مرض السكري.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الاستعمالات العلاجية:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;على بايوغليتازون.&nbsp;وهو دواء لعلاج مرض السكري النوع الثاني (مرض السكري غير المعتمد على الأنسولين)، عندما يعتبر ميتفورمين غير مناسب أو غير فعال بشكل كاف. يتطور مرض السكري هذا عادة في مرحلة البلوغ.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يساعد&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;على السيطرة على مستوى السكر في الدم عندما يكون لديك مرض السكري النوع الثاني من خلال مساعدة جسمك على الاستفادة بشكل أفضل من الأنسولين الذي ينتجه.&nbsp;سوف يتحقق طبيبك ما إذا&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;يعمل بعد 3 إلى 6 أشهر من بدء استعمال هذا الدواء.</p><p>يمكن استعمال جليران<!--[if gte vml 1]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /> لوحده في المرضى غير القادرين على تناول&nbsp;ميتفورمين، وعندما يخفق العلاج مع إتباع نظام غذائي وممارسة التمارين الرياضية للسيطرة على نسبة السكر في الدم أو قد يضاف إلى العلاجات الأخرى (مثل&nbsp;الميتفورمين&nbsp;،&nbsp;سالفونيل يوريا&nbsp;أو الأنسولين) والتي لم تكن فعالة في توفير سيطرة كافية على نسبة السكر في الدم.</p><p>إن هذا الدواء هو للاستعمال التشخيصي فقط.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ.</strong>&nbsp;<strong>موانع</strong><strong> </strong><strong>استعمال </strong><strong>جليران</strong><strong><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong></p><p>- إذا كنت تعاني من حساسية شديدة (التحسس) لمادة بايوغليتازون أو لأي من المكونات الأخرى الموجودة في&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong><strong>.</strong></p><p>- إذا كنت تعاني من قصور القلب أو قصور القلب المسبق.</p><p>- إذا كنت تعاني من مرض في الكبد.</p><p>- إذا كنت تعاني من الحماض الكيتوني السكري (يسبب مضاعفات مرض السكري فقدان الوزن السريع، والغثيان أو القيء).</p><p>- إذا كنت تعاني أو عانيت مسبقا من سرطان المثانة.</p><p>- إذا كنت تعاني من وجود دم في البول ولم يقم طبيبك بفحصه بعد.</p><p><strong>&nbsp;</strong></p><p><strong>ب.</strong>&nbsp;<strong>الاحتياطات</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>جليران</strong><strong><!--[if gte vml 1]><v:shape id="_x0000_i1027" type="#_x0000_t75"
 style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong><strong>&nbsp;</strong></p><p>أخبر طبيبك قبل البدء في تناول هذا الدواء</p><p><strong>قصور القلب وتأثيرات قلبية أخرى:</strong> بايوغليتازون، مثل باقي مجموعة الثيازوليديندايون الاخرى، يمكن أن يتسبب باحتباس السوائل عند استعماله لوحده أو بالتزامن مع أدوية أخرى تعالج مرض السكر، بما في ذلك الأنسولين.&nbsp;قد يؤدي إلى احتباس السوائل أو تفاقم القصور القلبي.&nbsp;يجب مراقبة المرضى لأعراض وعلامات قصور القلب.&nbsp;إذا تطورت هذه العلامات والأعراض يجب علاج قصور القلب وفقا للمعايير الأساسية الحالية.</p><p>وعلاوة على ذلك، يجب النظر في وقف أو تخفيض جرعة بايوغليتازون.</p><p>قد يكون هناك زيادة في فرصة وجود سرطان المثانة عند تناول بايوغليتازون.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من احتباس السوائل أو لديك مشكلة القصور القلبي ولا سيما إذا كنت أكثر من 75 سنة.&nbsp;إذا كنت تتناول أدوية مضادة للالتهابات والتي يمكن أيضا أن تسبب احتباس السوائل والتورم، يجب أيضا إخبار الطبيب بذلك.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نوع خاص من أمراض العين السكري يسمى وذمة البقعة الصفراء (تورم الجزء الخلفي من العين).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تكيس المبايض (متلازمة المبيض ذو الأكياس المتعددة).&nbsp;قد يكون هناك زيادة احتمال الحمل لديك؛ قد تستعيدين الإباضة مرة أخرى عند تناول&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>.&nbsp;إذا كان هذا ينطبق عليك، استعمل وسائل منع الحمل المناسبة لتجنب احتمال حدوث حمل غير مخطط له.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلة في الكبد أو القلب.&nbsp;قبل البدء في تناول&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape id="_x0000_i1029" type="#_x0000_t75"
 style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;سيتوجب عليك اعطاء عينة من الدم تؤخذ لفحص وظائف الكبد.&nbsp;هذا الاختبار يمكن أن يتكرر على فترات.&nbsp;بعض المرضى الذين يعانون من مرض السكري النوع الثاني طويل الأمد وأمراض القلب أو السكتة الدماغية السابقة والذين تم علاجهم <strong>بجليران</strong><strong><!--[if gte vml 1]><v:shape id="_x0000_i1030" type="#_x0000_t75"
 style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;و الأنسولين يشهدون تطور في قصور القلب.&nbsp;يجب إبلاغ الطبيب في أقرب وقت ممكن إذا واجهت علامات قصور القلب مثل ضيق غير عادي في التنفس أو زيادة سريعة في الوزن أو حدوث وذمة.</p><p>إذا كنت تتناول&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1031" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;مع أدوية أخرى لمرض السكري، فمن الأرجح أن نسبة السكر في الدم يمكن أن تقع تحت المستوى العادي (نقص سكر الدم).</p><p>أيضا قد تواجه انخفاضا في عدد خلايا الدم (الأنيميا).</p><p>كسور في العظام</p><p>تم ملاحظة عدد أعلى من كسور العظام في المرضى، ولا سيما النساء اللواتي يتناولن بايوغليتازون.&nbsp;سوف يأخذ طبيبك هذا بعين الاعتبار عند علاج مرض السكري لديكِ.</p><p><strong>الأطفال</strong></p><p>لا ينصح باستعماله في الأطفال دون سن 18 عاما.</p><p><strong>&nbsp;</strong></p><p><strong>ج.</strong>&nbsp;<strong>التداخلات</strong><strong> </strong><strong>الدوائية</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أخذ</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>المستحضر</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>أعشاب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مكملات غذائية</strong></p><p>يرجى إخبار الطبيب أو الصيدلاني إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p>يمكنك مواصلة تناول الأدوية الأخرى، عند تناول <strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1032" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>.&nbsp;ومع ذلك، فمن المرجح بصفة خاصة أن تؤثر بعض الأدوية على نسبة السكر في الدم:</p><p>- جيمفيبروزيل (التي تستعمل لخفض الكولسترول)</p><p>- ريفامبيسين (المستعملة لعلاج السل وغيره من الأمراض)</p><p>أخبر طبيبك أو الصيدلاني إذا كنت تتناول أي من هذه.&nbsp;وسيتم فحص نسبة السكر في الدم، وربما تحتاج جرعة <strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1033" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;إلى تغيير.</p><p><strong>&nbsp;</strong></p><p><strong>د.</strong>&nbsp;<strong>تناول جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1034" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong><strong>&nbsp;مع الطعام والشراب</strong></p><p>يمكنك تناول هذا الدواء مع أو بدون الطعام.&nbsp;يجب ابتلاع الأقراص مع كوب من الماء.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>هـ.</strong>&nbsp;<strong>الحمل والرضاعة </strong></p><p>أخبري طبيبك إذا</p><p>- كنت حاملا، كنت تعتقدين بأنك قد تكون أو تخططين لأن تصبح حاملا.</p><p>- كنت تقومين بالرضاعة الطبيعية أو إذا كنت تخططين لإرضاع طفلك.</p><p>سوف ينصحك الطبيب بالتوقف عن هذا الدواء.</p><p><strong>و.</strong>&nbsp;<strong>تأثير</strong><strong> </strong><strong>جليران</strong><strong><!--[if gte vml 1]><v:shape id="_x0000_i1035"
 type="#_x0000_t75" style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong><strong> </strong><strong>على</strong><strong> </strong><strong>القيادة</strong><strong> </strong><strong>واستعمال</strong><strong> </strong><strong>الآلات</strong></p><p>لا يؤثر بايوغليتازون على قدرتك على القيادة أو استعمال الآلات ولكن يجب اتخاذ الحيطة والحذر إذا واجهت رؤية غير طبيعية.</p><p><strong>&nbsp;</strong></p><p><strong>ز.</strong>&nbsp;<strong>معلومات هامة حول بعض مكونات </strong><strong>جليران</strong><strong><!--[if gte vml 1]><v:shape id="_x0000_i1036"
 type="#_x0000_t75" style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong></p><p>تحتوي أقراص <strong>جليران</strong><strong><!--[if gte vml 1]><v:shape id="_x0000_i1037"
 type="#_x0000_t75" style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong> على مادة اللاكتوز.&nbsp;إذا قال لك طبيبك بانك تعاني من عدم تحمل لبعض السكريات، اتصل بطبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب تناول قرص واحد 15 ملغم، 30 ملغم أو 45 ملغم من بايوغليتازون مرة واحدة يوميا.&nbsp;إذا لزم الأمر قد يخبرك طبيبك بتناول جرعة مختلفة.</p><p>إذا كان لديك انطباع بأن تأثير&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;ضعيف للغاية، يجب أن تتحدث إلى الطبيب.</p><p>عندما تأخذ&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;بالترافق مع الأدوية الأخرى المستعملة لعلاج مرض السكري (مثل الانسولين، كلوربروباميد، غليبينكلاميد، جليكلازايد، تولبوتاميد)، سوف يخبرك طبيبك ما إذا كنت بحاجة لتناول جرعة أقل من الأدوية الخاصة بك.</p><p>سوف يطلب منك طبيبك أن تعمل اختبارات الدم بصورة دورية خلال فترة العلاج مع&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>.&nbsp;هذا للتأكد من أن الكبد يعمل بشكل طبيعي.</p><p>إذا كنت تتبع نظام غذائي خاص لمرضى السكري، يجب أن تستمر فيه عند تناولك&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>.</p><p>يجب مراقبة وزنك على فترات منتظمة؛&nbsp;عند زيادة وزنك، أخبر طبيبك.</p><p>&nbsp;</p><p><strong>أ.</strong>&nbsp;<strong>إذا تناولت</strong><strong> جليران</strong><strong><!--[if gte vml 1]><v:shape id="_x0000_i1029"
 type="#_x0000_t75" style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong><strong>&nbsp;أكثر مما يجب</strong></p><p>إذا تناولت الكثير من الأقراص من غير قصد، أو إذا تناول الدواء الخاص بك شخص آخر أو طفل، يجب التحدث إلى الطبيب أو الصيدلاني فورا.&nbsp;يمكن أن تنخفض نسبة السكر في الدم عن المستوى العادي ويمكن تعديله عن طريق تناول السكر.&nbsp;فمن المستحسن أن تحمل بعض الكتل السكرية، الحلويات، البسكويت أو عصير الفواكه السكري.</p><p><strong>&nbsp;</strong></p><p><strong>ب.</strong>&nbsp;<strong>إذا نسيت تناول </strong><strong>جليران</strong><strong><!--[if gte vml 1]><v:shape id="_x0000_i1030"
 type="#_x0000_t75" style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong></p><p>تناول&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1031" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;بشكل يومي كما هو مقرر.&nbsp;ولكن إذا نسيت الجرعة، فقط استمر في الجرعة التالية كالمعتاد.&nbsp;لا تتناول جرعة مضاعفة لتعويض القرص المنسي.</p><p><strong>&nbsp;</strong></p><p><strong>ج.</strong>&nbsp;<strong>إذا توقفت عن تناول </strong><strong>جليران</strong><strong><!--[if gte vml 1]><v:shape id="_x0000_i1032"
 type="#_x0000_t75" style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong></p><p>يجب استعمال<strong> جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1033" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong> يوميا ليعمل بشكل صحيح.&nbsp;إذا توقفت عن استعمال&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1034" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong><strong>،</strong>&nbsp;فإن نسبة السكر في الدم قد ترتفع.&nbsp;تحدث إلى طبيبك قبل التوقف عن العلاج.</p><p>&nbsp;</p><p>إذا كان لديك أي أسئلة أخرى عن استعمال هذا الدواء، اسأل طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية<strong>، </strong><strong>جليران</strong><strong><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong> يمكن أن يسبب أعراض جانبية، بالرغم من أنها قد لا تحدث للجميع.</p><p>على وجه الخصوص، عانى المرضى من حدوث الآثار الجانبية الخطيرة التالية:</p><p>قد حدث قصور القلب بصورة شائعة (1-10 أشخاص من كل 100 شخص) في المرضى الذين يتناولون&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;بالترافق مع الأنسولين.&nbsp;تشمل الأعراض ضيق في التنفس غير عادي أو زيادة سريعة في الوزن أو تورم موضعي (وذمة).&nbsp;إذا واجهت أي من هذه الآثار، وخاصة إذا كنت فوق سن الـ 65، أطلب المشورة الطبية على الفور.</p><p>قد حدث سرطان المثانة بصورة غير شائعة (1 - 10 أشخاص من كل 1000 شخص) في المرضى الذين يتناولون&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>.&nbsp;تشمل العلامات والأعراض دم في البول، وألم عند التبول أو الحاجة المفاجئة للتبول.&nbsp;إذا كنت تواجه أي من هذه الآثار، يجب عليك التحدث إلى الطبيب في أقرب وقت ممكن.</p><p>&nbsp;</p><p>كما حدث تورم موضعي (وذمة) بصورة شائعة جدا في المرضى الذين يتناولون&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;بالترافق مع الأنسولين.&nbsp;إذا كنت تواجه هذه الآثار الجانبية، يجب عليك التحدث إلى الطبيب في أقرب وقت ممكن.</p><p>وقد تم الإبلاغ عن حدوث كسور في العظام بصورة شائعة (1-10 أشخاص من كل 100 شخص) في النساء المرضى الذين يتناولن&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1029" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>.&nbsp;إذا واجهتي هذه الآثار الجانبية، يجب عليك التحدث إلى الطبيب في أقرب وقت ممكن.</p><p>وحدث أيضا عدم وضوح في الرؤية بسبب التورم (أو السوائل) في الجزء الخلفي من العين (تواتر حدوثه غير معروف) في المرضى الذين يتناولون&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape id="_x0000_i1030"
 type="#_x0000_t75" style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>.&nbsp;إذا كنت تواجه مثل هذه الأعراض لأول مرة، يجب عليك التحدث إلى الطبيب في أقرب وقت ممكن. أيضا، إذا كنت مسبقا تعاني بالفعل من عدم وضوح الرؤية ولكن الأعراض تزداد سوءا، يجب عليك التحدث إلى الطبيب في أقرب وقت ممكن.</p><p>وقد تم الإبلاغ عن حدوث الحساسية (تواتر حدوثه غير معروف) في المرضى الذين يتناولون&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shape
 id="_x0000_i1031" type="#_x0000_t75" style='width:6.6pt;height:10.8pt;
 visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>.&nbsp;إذا كنت تعاني من رد فعل حساسية خطير، بما في ذلك احمرار مثل الشرى وتورم في الوجه والشفتين واللسان، أو الحلق التي قد تسبب صعوبة في التنفس أو البلع يجب عليك التوقف عن تناول هذا الدواء والتحدث مع طبيبك في أقرب وقت ممكن.</p><p>الآثار الجانبية الأخرى التي يعاني منها بعض المرضى الذين يتناولون&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;هي:</p><p><strong>شائعة (تؤثر 1-10 أشخاص من كل 100 شخص)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الجهاز التنفسي</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية غير طبيعية</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدران</p><p><strong>غير شائعة (تؤثر 1-10 أشخاص من كل 1000 شخص)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجيوب الأنفية</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم (الأرق)</p><p><strong>غير معروفة (لا يمكن تقدير تواتر حدوثه من البيانات المتاحة) </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في إنزيمات الكبد</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية</p><p>&nbsp;</p><p>تشمل الآثار الجانبية الأخرى التي يعاني منها بعض المرضى عند تناول <strong>جليران</strong><strong><!--[if gte vml 1]><v:shape id="_x0000_i1026"
 type="#_x0000_t75" style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong><strong> </strong>مع الأدوية التي تعالج مرض السكر الأخرى هي:</p><p><strong>شائعة جدا (يؤثر على أكثر من 1 شخص من كل 10 أشخاص)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة السكر في الدم (نقص سكر الدم)</p><p><strong>شائعة (تؤثر 1-10 أشخاص من كل 100 شخص)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العجز الجنسي</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الظهر</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض طفيف في عدد خلايا الدم الحمراء</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ البطن</p><p><strong>غير شائعة (تؤثر 1-10 أشخاص من كل 1000 شخص)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود السكر في البول، والبروتينات في البول</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في الأنزيمات</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الشهية</p><p>&nbsp;</p><p>إذا حدث أي من هذه الآثار الجانبية الخطيرة، أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول وبصر الأطفال.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ تحت &deg;30 م، بعيداً عن الرطوبة.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل&nbsp;<strong>جليران</strong><strong><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong>&nbsp;بعد تاريخ انتهاء الصلاحية(Exp. Date) &nbsp;التي توضع على العلبة الخارجية.&nbsp;يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p>يجب عدم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية.&nbsp;اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد مطلوبة.&nbsp;وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ.</strong>&nbsp;<strong>ما هي محتويات </strong><strong>جليران</strong><strong><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:6.6pt;height:10.8pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="9" height="14" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></strong><strong> </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة&nbsp;هي بايوغليتازون.</p><p><strong>جليران</strong>&nbsp;<strong>15:</strong> كل قرص يحتوي على بايوغليتازون هايدروكلورايد ما يعادل 15 ملغم بايوغليتازون.</p><p><strong>جليران</strong>&nbsp;<strong>30:</strong> كل قرص يحتوي على بايوغليتازون هايدروكلورايد ما يعادل 30 ملغم بايوغليتازون.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى: لاكتوز، هيدروكسي بروبيل سيلليلوز ، كالسيوم كاربوكسي ميثيل سيلليلوز ، ماغنيسيوم&nbsp; ستيريت.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            •	أقراص 
•	الوصف الخارجي:
جليران  15 ملغم أقراص: أقراص مربعة ذات حواف دائرية بيضاء اللون مسطحة منقوشة برمز "E44" على جهة وفارغة على الجهه الآخرى.
جليران  30 ملغم أقراص: أقراص بيضاء اللون حجم 7 ملم مستديرة مسطحة منقوشة برمز "T54".
•	جليران   متوفر في حجم العبوة التالية 30 قرصا˝/عبوة /علبة.
عبوات المستشفيات متوفرة أيضاً.
جليران   أقراص معبأة في عبوات بلاستيكية بيضاء مغلقة بغطاء بلاستيكي أبيض مقاوم للأطفال تحتوي على اكياس سيليكا ثم محاطة بلاصق داخلي ملون ومن ثم معبأة في عبوات كرتون ملونة مع نشرات داخلية.


        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إم إس فارما السعودية</p><p>الرياض ، المملكة العربية السعودية</p><p>&nbsp;&nbsp;&nbsp; info-ksa@mspharma.com</p><p>&nbsp;</p><p><strong>صنعت بواسطة :</strong></p><p>المتحدة للصناعات الدوائية <strong>لصالح </strong>إم إس فارما &ndash; المملكة العربية السعودية .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Jan /2020
SPM190581
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 GLERAN® 30mg Tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Material Name	Function	Amount per one tablet
Pioglitazone HCl	Active material	33.73 mg
Lactose, regular	Diluent	72.0 mg
Hydroxy propyl cellulose	Binder	1.700 mg
Calcium Carboxy Methyl Cellulose	Disintegrant	12.00 mg
Mg Stearate	Lubricant	0.600 mg

*   2% Overage to compensate for API potency & water content.
For a full list of excipients, see section 6.1 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablets
GLERAN® 30mg Tablets: White 7mm round flat tablets embossed with T54.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:</p><p>&nbsp;<strong>Monotherapy</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.</p><p><strong>Dual oral therapy</strong> in combination with</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea.</p><p><strong>Triple oral therapy</strong> in combination with</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.</p><p>&nbsp;</p><p>After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1<sub>c</sub>). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Route of administration: </strong>Orally</p><p><strong><u>Posology</u></strong></p><p>Pioglitazone treatment may be initiated at 15 mg or 30 mg once daily. The dose may be increased in increments up to 45 mg once daily.</p><p>In combination with insulin, the current insulin dose can be continued upon initiation of pioglitazone therapy. If patients report hypoglycaemia, the dose of insulin should be decreased.</p><p><strong><u>Special population</u></strong></p><p><strong><em>Elderly</em></strong></p><p>No dose adjustment is necessary for elderly patients. Physicians should start treatment with the lowest available dose and increase the dose gradually, particularly when pioglitazone is used in combination with insulin.</p><p><strong><em>Renal impairment</em></strong></p><p>No dose adjustment is necessary in patients with impaired renal function (creatinine clearance &gt; 4 ml/min). No information is available from dialysed patients therefore pioglitazone should not be used in such patients.</p><p><em>Hepatic impairment</em></p><p>Pioglitazone should not be used in patients with hepatic impairment.</p><p><strong><u>Paediatric population</u></strong></p><p>The safety and efficacy of Pioglitazone&nbsp; in children and adolescents under 18 years of age have not been established. No data are available.</p><p><strong><u>Method of administration</u></strong></p><p>Pioglitazone tablets are taken orally once daily with or without food. Tablets should be swallowed with a glass of water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Pioglitazone is contraindicated in patients with: 
-	Hypersensitivity to the active substance or to any of the excipients 
-	Cardiac failure or history of cardiac failure (NYHA stages I to IV) 
-	Hepatic impairment 
-	Diabetic ketoacidosis 
-	Current bladder cancer or a history of bladder cancer 
-	Uninvestigated macroscopic haematuria

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="3" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong><em>Fluid retention and cardiac failure</em></strong></p><p>Pioglitazone can cause fluid retention, which may exacerbate or precipitate heart failure. When treating patients who have at least one risk factor for development of congestive heart failure (e.g. prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start with the lowest available dose and increase the dose gradually. Patients should be observed for signs and symptoms of heart failure, weight gain or oedema; particularly those with reduced cardiac reserve. There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. Patients should be observed for signs and symptoms of heart failure, weight gain and oedema when pioglitazone is used in combination with insulin. Since insulin and pioglitazone are both associated with fluid retention, concomitant administration may increase the risk of oedema. Post marketing cases of peripheral oedema and cardiac failure have also been reported in patients with concomitant use of pioglitazone and nonsteroidal anti-inflammatory drugs, including selective COX-2 inhibitors. Pioglitazone should be discontinued if any deterioration in cardiac status occurs.</p><p><strong><em>Elderly</em></strong></p><p>Combination use with insulin should be considered with caution in the elderly because of increased risk of serious heart failure.</p><p>In light of age- related risks (especially bladder cancer, fractures and heart failure), the balance of benefits and risks should be considered carefully both before and during treatment in the elderly.</p><p><strong><em>Bladder Cancer</em></strong></p><p>Small increased risk of bladder cancer in diabetic patients treated with pioglitazone in particular in patients treated for the longest durations and with the highest cumulative doses. A possible risk after short term treatment cannot be excluded.</p><p>Risk factors for bladder cancer should be assessed before initiating pioglitazone treatment (risks include age, smoking history, exposure to some occupational or chemotherapy agents e.g. cyclophosphamide or prior radiation treatment in the pelvic region). Any macroscopic haematuria should be investigated before starting pioglitazone therapy.</p><p>Patients should be advised to promptly seek the attention of their physician if macroscopic haematuria or other symptoms such as dysuria or urinary urgency develop during treatment.</p><p><strong><em>Monitoring of liver function</em></strong></p><p>There have been rare reports of hepatocellular dysfunction during post-marketing experience. It is recommended, therefore, that patients treated with pioglitazone undergo periodic monitoring of liver enzymes. Liver enzymes should be checked prior to the initiation of therapy with pioglitazone in all patients. Therapy with pioglitazone should not be initiated in patients with increased baseline liver enzyme levels (ALT &gt; 2.5 X upper limit of normal) or with any other evidence of liver disease.</p><p>Following initiation of therapy with pioglitazone, it is recommended that liver enzymes be monitored periodically based on clinical judgement. If ALT levels are increased to 3 X upper limit of normal during pioglitazone therapy, liver enzyme levels should be reassessed as soon as possible.</p><p>&nbsp;</p><p>If ALT levels remain &gt; 3 X the upper limit of normal, therapy should be discontinued. If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia and/or dark urine, liver enzymes should be checked. The decision whether to continue the patient on therapy with pioglitazone should be guided by clinical judgement pending laboratory evaluations. If jaundice is observed, the medicinal product should be discontinued.</p><p><strong><em>Weight gain</em></strong></p><p>With pioglitazone there was evidence of dose related weight gain, which may be due to fat accumulation and in some cases associated with fluid retention. In some cases weight increase may be a symptom of cardiac failure, therefore weight should be closely monitored. Part of the treatment of diabetes is dietary control. Patients should be advised to adhere strictly to a calorie-controlled diet.</p><p><strong><em>Haematology</em></strong></p><p>There was a small reduction in mean haemoglobin and haematocrit (relative reduction) during therapy with pioglitazone, consistent with haemodilution.</p><p><strong><em>Hypoglycaemia</em> </strong></p><p>As a consequence of increased insulin sensitivity, patients receiving pioglitazone in dual or triple oral therapy with a sulphonylurea or in dual therapy with insulin may be at risk for dose-related hypoglycaemia, and a reduction in the dose of the sulphonylurea or insulin may be necessary.</p><p><strong><em>Eye disorders</em> </strong></p><p>Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone. Many of these patients reported concurrent peripheral oedema. It is unclear whether or not there is a direct association between pioglitazone and macular oedema but prescribers should be alert to the possibility of macular oedema if patients report disturbances in visual acuity; an appropriate ophthalmological referral should be considered.</p><p><strong><em>Others</em></strong></p><p>The risk of fractures should be considered in the long term care of patients treated with pioglitazone.</p><p>As a consequence of enhancing insulin action, pioglitazone treatment in patients with polycystic ovarian syndrome may result in resumption of ovulation. These patients may be at risk of pregnancy. Patients should be aware of the risk of pregnancy and if a patient wishes to become pregnant or if pregnancy occurs, the treatment should be discontinued.</p><p>Pioglitazone should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin). Glycaemic control should be monitored closely. Pioglitazone dose adjustment within the recommended posology or changes in diabetic treatment should be considered.</p><p><strong>GLERAN<sup>&reg;</sup></strong> tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.</p></td><td>&nbsp;</td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Co-administration of pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea. No induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4.</p><p>Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC of pioglitazone. Since there is a potential for an increase in dose-related adverse events, a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. Close monitoring of glycaemic control should be considered<strong>. </strong>Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone. The pioglitazone dose may need to be increased when rifampicin is concomitantly administered. Close monitoring of glycaemic control should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pregnancy</em></strong></p><p>There are no adequate human data to determine the safety of pioglitazone during pregnancy. Foetal growth restriction was apparent in animal studies with pioglitazone. This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy thereby reducing the availability of metabolic substrates for foetal growth. The relevance of such a mechanism in humans is unclear and pioglitazone should not be used in pregnancy.</p><p><strong><em>Breastfeeding</em></strong></p><p>Pioglitazone has been shown to be present in the milk of lactating rats. It is not known whether pioglitazone is secreted in human milk. Therefore, pioglitazone should not be administered to breast-feeding women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>GLERAN<sup>&reg;</sup></strong> has no or negligible effect on the ability to drive and use machines. However patients who experience visual disturbance should be cautious when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Frequencies are defined as: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to&lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing incidence and seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:110%"><tbody><tr><td rowspan="3" style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td colspan="7" style="vertical-align:top"><p><strong>Frequency of adverse reactions of pioglitazone by treatment regimen</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Monotherapy</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Combination</strong></p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>with metformin</strong></p></td><td style="vertical-align:top"><p><strong>with sulphonylurea</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>with metformin and sulphonylurea</strong></p></td><td style="vertical-align:top"><p><strong>with insulin</strong></p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>upper respiratory tract infection</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>bronchitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>sinusitis</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>uncommon</p></td><td colspan="2" style="vertical-align:top"><p>uncommon</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>anaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Immune System Disorders</strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity and allergic reactions<sup>1</sup></p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>not known</p></td><td colspan="2" style="vertical-align:top"><p>not known</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>hypoglycaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>very common</p></td><td colspan="2" style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>appetite increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>hypoaesthesia</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>insomnia</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>uncommon</p></td><td colspan="2" style="vertical-align:top"><p>uncommon</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>visual disturbance<sup>2</sup></p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>macular oedema<sup>3</sup></p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>not known</p></td><td colspan="2" style="vertical-align:top"><p>not known</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>heart failure<sup>4</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (including cysts and polyps) </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>bladder cancer</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>uncommon</p></td><td colspan="2" style="vertical-align:top"><p>uncommon</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>flatulence</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>sweating</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>fracture bone</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>arthralgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>back pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>haematuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>glycosuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>proteinuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>erectile dysfunction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>very common</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>fatigue</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Investigations </strong></p></td><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>weight increased</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>blood creatine phosphokinase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>increased lactic dehydrogenase</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase increased<sup>5</sup></p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>not known</p></td><td colspan="2" style="vertical-align:top"><p>not known</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><sup>1 </sup>Postmarketing reports of hypersensitivity reactions in patients treated with pioglitazone have been reported. These reactions include anaphylaxis, angioedema, and urticaria.</p><p><sup>2 </sup>Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments.</p><p><sup>3</sup> Oedema was generally mild to moderate and usually did not require discontinuation of treatment.</p><p><sup>&nbsp;</sup></p><p><sup>4</sup> Heart failure has been reported with marketing use of pioglitazone, and more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure.</p><p><sup>5</sup> Mean levels of liver enzymes decreased with treatment with pioglitazone. Rare cases of elevated liver enzymes and hepatocellular dysfunction have occurred in post-marketing experience. Although in very rare cases fatal outcome has been reported, causal relationship has not been established.</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s): </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia: </strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; National Pharmacovigilance &amp; Drug Safety Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext.: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone : 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States: </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:678px"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The maximum reported dose of 120 mg/day for four days, then 180 mg/day for seven days was not associated with any symptoms.</p><p>Hypoglycaemia may occur in combination with sulphonylureas or insulin. Symptomatic and general supportive measures should be taken in case of overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Drugs used in diabetes, blood glucose lowering drugs, excl. insulins; <strong>ATC code:</strong> A10BG03.</p><p>Pioglitazone effects may be mediated by a reduction of insulin resistance. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.</p><p>Fasting and postprandial glycaemic control is improved in patients with type 2 diabetes mellitus. The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations.</p><p>Pioglitazone improves beta cell function as well as increasing insulin sensitivity.</p><p>Pioglitazone consistently gave a statistically significant reduction in the albumin/creatinine ratio compared to baseline.</p><p>Pioglitazone was associated with significant weight gain. Visceral fat was significantly decreased, while there was an increase in extra-abdominal fat mass. Similar changes in body fat distribution on pioglitazone have been accompanied by an improvement in insulin sensitivity.</p><p>Reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed, with small, but not clinically significant increases in LDL-cholesterol levels.</p><p>Pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides. These effects were independent of pioglitazone&#39;s effects on glycaemia and were statistically significant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Absorption</em></strong></p><p>Following oral administration, pioglitazone is rapidly absorbed, and peak plasma concentrations of unchanged pioglitazone are usually achieved 2 hours after administration. Proportional increases of the plasma concentration were observed for doses from 2&ndash;60 mg. Steady state is achieved after 4&ndash;7 days of dosing. Repeated dosing does not result in accumulation of the compound or metabolites. Absorption is not influenced by food intake. Absolute bioavailability is greater than 80%.</p><p><strong><em>Distribution</em></strong></p><p>The estimated volume of distribution in humans is 0.25 l/kg.</p><p>Pioglitazone and all active metabolites are extensively bound to plasma protein (&gt; 99%).</p><p><strong><em>Biotransformation</em></strong></p><p>Pioglitazone undergoes extensive hepatic metabolism by hydroxylation of aliphatic methylene groups. This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree. Three of the six identified metabolites are active (M-II, M-III, and M-IV). When activity, concentrations and protein binding are taken into account, pioglitazone and metabolite M-III contribute equally to efficacy. On this basis M-IV contribution to efficacy is approximately three-fold that of pioglitazone, whilst the relative efficacy of M-II is minimal.</p><p>There is no induction of the main inducible P450 isoenzymes 1A, 2C8/9, and 3A4 in man.</p><p>Pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the plasma concentration of pioglitazone.<strong><em>&nbsp;</em></strong></p><p><strong><em>Elimination</em></strong></p><p>Mainly in faeces (55%) and a lesser amount in urine (45%). The mean plasma elimination half-life of unchanged pioglitazone in man is 5 to 6 hours and for its total active metabolites 16 to 23 hours.</p><p><strong><em>Elderly</em></strong></p><p>Steady state pharmacokinetics are similar in patients age 65 and over and young subjects.</p><p><strong><em>Patients with renal impairment</em></strong></p><p>In patients with renal impairment, plasma concentrations of pioglitazone and its metabolites are lower than those seen in subjects with normal renal function, but oral clearance of parent substance is similar. Thus free (unbound) pioglitazone concentration is unchanged.</p><p><strong><em>Patients with hepatic impairment</em></strong></p><p>Total plasma concentration of pioglitazone is unchanged, but with an increased volume of distribution. Intrinsic clearance is therefore reduced, coupled with a higher unbound fraction of pioglitazone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose</p><p>Hydrxypropyl cellulose</p><p>Calcium carboxymethyl cellulose</p><p>Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below&nbsp;30&ordm;C, protected from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>GLERAN<sup>&reg;</sup> 30mg Tablets</strong> are packed in White 60ml high density polyethylene jar of polypropylene CRC, with adhesive label containing Silica gel bags, in carton box with a multi folded leaflet.</p><p>&nbsp;</p><p><strong>Pack size:</strong> 30 Tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The United Pharmaceutical Mfg. Co. Ltd.
P.O. Box 69, Amman 11591-Jordan
Tel: + 962 (6) 416 2901      
Fax: + 962 (6) 416 2905 
E-mail:  Info@upm.com.jo

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November, 2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>